Loading…
Utilizing miRNA-613 as novel therapy for mucoepidermoid carcinoma
•Mucoepidermoid carcinoma (MEC) poses significant treatment challenges.•miR-613 targets critical oncogenic pathways and suppresses tumor growth.•Integrating miR-613 into existing treatments is a promising avenue for MEC.•Targeted miR-613 therapy potentially improves MEC patient outcomes.
Saved in:
| Published in: | Oral oncology reports 2024-06, Vol.10, p.100407, Article 100407 |
|---|---|
| Main Author: | |
| Format: | Article |
| Language: | English |
| Citations: | Items that this one cites |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | •Mucoepidermoid carcinoma (MEC) poses significant treatment challenges.•miR-613 targets critical oncogenic pathways and suppresses tumor growth.•Integrating miR-613 into existing treatments is a promising avenue for MEC.•Targeted miR-613 therapy potentially improves MEC patient outcomes. |
|---|---|
| ISSN: | 2772-9060 2772-9060 |
| DOI: | 10.1016/j.oor.2024.100407 |